Share ownership Monte Rosa Therapeutics, Inc.

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-14 EDT			5-day change	1st Jan Change
23.46 ^USD	+6.73%		-3.85%	+49.62%

06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index	CI

Share class: Monte Rosa Therapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	84,479,418	83,991,546 ( 99.42 %)	0	99.42 %

Major shareholders: Monte Rosa Therapeutics, Inc.

Name	Stocks	%	Valuation
T. Rowe Price Associates, Inc. (IM) 10.49 %	8,861,282	10.49 %	214 M $
T. Rowe Price International Ltd. 7.955 %	6,720,188	7.955 %	163 M $
NEA Management Co. LLC 7.922 %	6,692,298	7.922 %	162 M $
Dimension Management LP 6.704 %	5,663,265	6.704 %	137 M $
BlackRock Advisors LLC 6.249 %	5,279,112	6.249 %	128 M $
TCG Crossover Management LLC 5.471 %	4,622,151	5.471 %	112 M $
TCG Crossover Management LLC 5.471 %	4,622,151	5.471 %	112 M $
BVF, Inc. 5.28 %	4,460,886	5.28 %	108 M $
Baker Bros. Advisors LP 5.144 %	4,345,736	5.144 %	105 M $
Baker Bros. Advisors LP 5.144 %	4,345,736	5.144 %	105 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	118.35%
Others	12.97%
State Street Corp.	3.97%
Individuals	1.06%
Alphabet, Inc.	0.81%
Manulife Financial Corp.	0.25%
SEI Investments Co.	0.09%
Schweizerische Nationalbank	0.07%
The Allstate Corp.	0.03%
Governments	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	119.08%
United Kingdom	10.74%
Switzerland	3.65%
Australia	1.19%
Individuals	1.06%
Germany	0.84%
Canada	0.64%
Ireland	0.22%
Cayman Islands	0.07%
Hong Kong	0.06%
Luxembourg	0.03%
China	0.03%
Norway	0.01%

Based on 1000 largest holdings

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the bodyâ€™s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Employees

187

Sector

Biotechnology & Medical Research

More about the company